drugset / Trial / NCT05550636

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood

NCT05550636

Phase 1 Completed 15 enrolled Boehringer Ingelheim
NaSequentialOpen-labelTreatment

Summary

The main objective of this trial is to investigate the induction effect of multiple doses of BI 1015550 on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.

Timeline

Start
2022-10-11
Primary completion
2022-12-19
Completion
2022-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule
Subject Nerandomilast Small molecule

Indications

No indication recorded.